Top Story

VIDEO: Ipilimumab plus nivolumab conferred high response rates in melanoma

VIDEO: Ipilimumab plus nivolumab conferred high response rates in melanoma
April 27, 2015

F. Stephen Hodi, Jr., MD, director of the melanoma center at Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School, discusses results of a randomized phase 2 trial which demonstrated that the addition of nivolumab to ipilimumab improved outcomes in patients with advanced melanoma, particularly those patients who had BRAF wild-type disease.

“This is really confirming our suspicions that combining two main checkpoints together for the treatment of melanoma [would improve outcomes].  We also await the phase 3 trial of the combination versus either agent alone in a three-arm study that has completed accrual already,” Hodi told HemOnc Today.

Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting Meeting News CoverageVideo

Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting

April 26, 2015
NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of hematology and oncology at St. Luke’s Cancer…
Meeting News Coverage

Next generation sequencing increases actionable mutation detection in malignant melanoma

April 26, 2015
NEW YORK — The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations among patients with…
Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma Meeting News CoverageVideo

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University, presents data from patients with melanoma who were…
Meeting News Coverage

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015
NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University…
More »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
morganatic-roan